Company intelligence / Profile preview

Acrotech Biopharma Inc

East Windsor, New Jersey, United Statesacrotechbiopharma.com ↗

Ownership: Private
Employees: ~56
Development stage: Commercial

Overview

Acrotech Biopharma has several approved drugs, including Ryzneuta™ for chemotherapy-induced neutropenia, pralatrexate and belinostat for peripheral T-cell lymphoma, levoleucovorin for drug intoxication, and melphalan hydrochloride for multiple myeloma. Ryzneuta™ was recently FDA-approved following a global clinical program involving over 1,200 subjects. The company continues to develop additional programs in oncology and hematology.

Therapeutic areas: Oncology
Modalities: Small moleculesBiologicsMonoclonal antibodiesProteins and peptides
Industry: Biotech

Drug pipeline

1 asset

vincristine sulfate liposome

Partnerships

Evive Biotech/Yifan Pharmaceutical Co., Ltd. – partnership on Ryzneuta™ commercialization in the US

Beyond the preview

Go deeper on Acrotech Biopharma Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acrotech Biopharma Inc.

Explore the full profile